Endothelin Antagonist Keeps Patients with Hormone Refractory Prostate Cancer Alive Longer
Nicholas James
Gordon McVie
REFERENCE: Abstract: 3LB (Presidential Session), ECCO 14, The European Cancer Conference, Barcelona, 23 – 27 September 2007
NICHOLAS JAMES, Birmingham University
COMMENT: GORDON MCVIE, European Institute of Oncology, Milan
A new drug has improved overall survival
NICHOLAS JAMES, Birmingham University
COMMENT: GORDON MCVIE, European Institute of Oncology, Milan
A new drug has improved overall survival